New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:07 EDTGALEGalena acquires Mills Pharmaceuticals in share transaction
Galena Biopharma announced it has acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401, a patented, controlled release formulation of anagrelide. Galena expects to pursue the expedited 505(b)(2) regulatory pathway to seek approval of GALE-401 for the treatment of Essential Thrombocythemia, or ET. The company also believes GALE-401 meets the qualifications for orphan drug status. GALE-401 has an estimated peak market size of approximately $200M in the U.S. Under the terms of the agreement, Galena paid an up-front payment to Mills Pharmaceuticals' owners. Additionally, Mills Pharmaceuticals owners are eligible to receive one-time payments of up to 4M shares with the achievement of specified regulatory milestones. The owners of Mills Pharmaceuticals are also eligible to receive $3M upon FDA approval of a new drug application in respect to GALE-401. GALE-401 possesses a broad patent portfolio and provides intellectual property protection through at least 2029. Mills Pharmaceuticals is affiliated with Aceras Partners. Roth Capital Partners acted as financial advisor to Galena in this transaction.
News For GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
14:08 EDTGALEGalena files to sell 2M shares of common stock for holders
Subscribe for More Information
October 14, 2014
07:17 EDTGALEGalena receives notice of allowance of improvement patent for NeuVax in Japan
Galena Biopharma announced the notice of allowance from the Japanese Patent Office for NeuVax covering the use of NeuVax alone or in combination with other agents to prevent recurrence of any HER2/neu expressing breast cancer tumor having an immunohistochemistry level of 1+ or 2+, or a fluorescence in situ hybridization rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent will expire in 2027, not including any patent term extensions.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use